{"page_content": "Introduction COVID-19 Response\n2  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nHealthy People Healthy Society Healthy Planet A Healthy Amgen Appendix\nCorporate Governance   . . . . . 55\nBusiness Ethics   . . . . . . . . . . . . 56\nEthical Research   . . . . . . . . . . . 58\nPatient Safety and Product \nQuality   . . . . . . . . . . . . . . . . . . . 60\nCybersecurity and  \nData Privacy   . . . . . . . . . . . . . . . 63\nGovernment Affairs  \nand Public Policy  . . . . . . . . . . . 65\nWe value and welcome \nfeedback from all \nstakeholders  . Please \nsend comments or \nquestions about this \nreport to  \nESG@AMGEN .COMABOUT THIS REPORT \nThis report describes our progress from January \n1, 2021 to December 31, 2021 .  The content \nis informed by our ongoing monitoring of \ninternal and external stakeholder perspectives, \ndirect interactions with stakeholders, a review \nof relevant reporting standards and frameworks, \nand internal analyses of the alignment of \nenvironmental, social and governance (ESG) \ntopics with our strategy, mission and values  . \nAll of our worldwide business operations are \nincluded in this report unless otherwise stated  . \nThroughout this report, we also guide readers \nto additional sources of information online  . \nWe have prepared this report in alignment with \nthe Biopharma Investor ESG Communications \nGuidance (the \u201cGuidance\u201d) .  Launched in 2020, \nthe Guidance identifies high-priority ESG topics for the biopharmaceutical sector and \nrecommends how to structure information and \ndisclosures in a useful format for investors  . The \nGuidance integrates components and principles \nof the Sustainability Accounting Standards \nBoard (SASB) Biotechnology & Pharmaceuticals \nSustainability Accounting Standard, as well as \nthe Task Force on Climate-Related Financial \nDisclosures (TCFD) reporting standard  . Our \nreporting also reflects our alignment with \nthe United Nations (UN) Global Compact and \nSustainable Development Goals  . \nTABLE OF CONTENTS\nAbout This Report   . . . . . . . . . 2\nAbout Amgen   . . . . . . . . . . . . . 3\nAwards and Rankings   . . . . . . 5\nLeadership Message   . . . . . . . 6\nOur Approach to ESG   . . . . . . 7\n .  .  .  .  . 25 .  .  .  .  . 14 .  .  .  .  . 10 .  .  .  .  .  . 2  .  .  .  .  .  . 44\n .  .  .  .  .  . 53\n .  .  .  .  .  . 66COVID-19 Response   . . . . . . 11\nAccess to Medicines   . . . . . 16\nHealth Equity   . . . . . . . . . . . . 20\nDiversity, Inclusion and \nBelonging   . . . . . . . . . . . . . . . . 27\nHuman Capital \nManagement   . . . . . . . . . . . . . 33\nCommunity Investment   . . .37\nResponsible Sourcing   . . . . . 42Environmental \nSustainability   . . . . . . . . . . . . . . 46\nUN Global Communications \non Progress  . . . . . . . . . . . . . . . . 66\nCompany Performance \nData   . . . . . . . . . . . . . . . . . . . . . . . 67\n SASB Index   . . . . . . . . . . . . . . . . 68\nForward-Looking \nStatements   . . . . . . . . . . . . . . . . 74COVID-19 Response\nHealthy People\nHealthy SocietyHealthy Planet\nA Healthy AmgenIntroductionINTRODUCTION\nCOVER IMAGES: (Right) Senior Associate Scientist Asha Kelley \nin the discovery research lab, Thousand Oaks, California.\n(Far left) Induced Proximity Platform: the small molecule shown \nas green and blue balls (carbons and nitrogens) brings together a \ncomplex of four proteins (red, orange, beige and teal) that doesn\u2019t \nexist in nature. This results in the enzymatic destruction of the \nteal protein, which is a cancer-driving protein.Reference to our website is not \nintended to function as a \nhyperlink, and the information \ncontained on our website is not \nintended to be part of this report .Appendix", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 1, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}